Claim OwnershipProject Oncology®
Subscribed: 10Played: 82
Subscribe
© Copyright 2025 ReachMD. All rights reserved.
Description
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
178 Episodes
Reverse
Race-based spirometry adjustments have long influenced pulmonary risk assessments, often underestimating disease severity in Black patients. Hear from Dr. Ajay Sheshadri as he examines the historical misuse of race in lung function testing, explores race-neutral modeling in surgical risk prediction, and highlights the need for data-driven, continuous risk assessment tools in caring for patients with non-small cell lung cancer. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center.
As medicine shifts toward race-neutral lung function interpretation, new challenges emerge in ensuring equitable access to care. Dr. Ajay Sheshadri explores how race-neutral spirometry may impact patient selection for lung resection surgery and hematopoietic cell transplantation. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center.
A 2025 study in Chest evaluated PREDICT, a precision medicine program at a large academic-community practice, designed to streamline testing and expand access to personalized treatment for non-small cell lung cancer (NSCLC). Hear from ReachMD's Ryan Quigley as he shares the key impacts of this approach and implications for care delivery.
Guest: Alexis Leonard
Sickle cell disease management traditionally involves two primary treatment approaches: disease-modifying therapies and curative strategies. While disease-modifying therapies can help reduce complications associated with the disease, they do not correct or fix them, which is why curative strategies are appealing to some patients and physicians. Join Dr. Alexis Leonard as she discusses the current management landscape for sickle cell disease, including disease-modifying treatments, curative strategies, and potential gene therapies. Dr. Leonard works in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee.
Guest: Alexis Leonard
CRISPR technology, while relatively new, has shown potential in treating patients with sickle cell disease by increasing fetal hemoglobin. Though this gene therapy comes with safety considerations, refinements and advancements in CRISPR technology can offer new management options for sickle cell disease patients. Learn about the history of CRISPR as a sickle cell disease treatment and the future of this strategy with Dr. Alexis Leonard, who works in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee.
Guest: David Jacobsohn
Gene therapy is redefining the treatment landscape for sickle cell disease, with approaches like gene addition, gene editing, and fetal hemoglobin induction showing promise in reducing or even eliminating symptoms. However, while these therapies offer some advantages over allogeneic stem cell transplant, they also come with significant challenges. In a conversation with Ryan Quigley, Dr. David Jacobsohn discusses considerations for these therapeutic approaches and their potential impacts on care plans for sickle cell disease patients. Dr. Jacobsohn is the Division Chief of the Blood and Marrow Transplantation Program at Children’s National Hospital and Full Professor of Pediatrics at the George Washington University in Washington, DC.
Guest: Alexis Leonard
With two FDA-approved gene therapies, including the first CRISPR-based treatment, curative strategies for sickle cell disease are continuing to expand the treatment landscape. However, challenges remain in optimizing safety and accessibility, particularly for patients unable to tolerate current myeloablative conditioning. Learn about advancements in ex vivo editing, such as improved stem cell targeting and multiplex editing, and the possibility of in vivo approaches that may help transform sickle cell disease management with Dr. Alexis Leonard, who works in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathon B. Cohen, MD, MS
As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.
Host: Ashley Baker, MSN, PMHNP
Guest: Alyssa Schlenz
Guest: Shannon Phillps
Families of children with sickle cell disease have noted both an abundance of support and significant obstacles when accessing care, ranging from knowledgeable providers and flexible scheduling to transportation concerns and insurance holdups. Joining Ashley Baker to discuss their recent research on these key facilitators and barriers are Drs. Alyssa Schlenz and Shannon Phillips. Dr. Schlenz is an Associate Professor of Pediatrics at the University of Colorado School of Medicine, and Dr. Phillips is an Associate Professor in the College of Nursing at the Medical University of South Carolina.
Host: Hallie Blevins, PhD.
Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.
Host: Ryan Quigley
In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
Host: Marlene Mimi Maeusli, PhD.
A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.
Guest: Paola Marignani, PhD, EMBA
While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sairah Ahmed, MD
CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall response rate and sustained 24-month progression-free survival in relapsed/refractory marginal zone lymphoma. Here with Dr. Charles Turck to share the key efficacy and safety findings is Dr. Sairah Ahmed, Professor in the Department of Lymphoma and Myeloma and CAR T Program Director at MD Anderson Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Samuel Yamshon, MD
The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategies in combination with chemoimmunotherapy—they raise important questions around sequencing, durability, and patient selection. Joining Dr. Charles Turck to explore the real-world implications of this evolving approach is Dr. Samuel Yamshon, Director of the Cellular Therapy Service and an Assistant Professor of Medicine at Weill Cornell Medicine in New York.
Guest: Paola Marignani, PhD, EMBA
Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.
Guest: John Cho, MD, PhD, FRCPC
Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Guest: John Cho, MD, PhD, FRCPC
While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Host: Ryan Quigley
The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.
Guest: Jennifer Caudle, DO
Host: Patrick McGill, MD
Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cancers undetected until later stages. But multi-cancer early detection (MCED) testing is reshaping the landscape with blood-based analyses of cell-free DNA and methylation patterns to identify potential cancers earlier than traditional imaging. Designed for the general population over age 50, MCED testing complements rather than replaces standard screenings, helping detect cancers at stages when treatment is most effective. Joining Dr. Jennifer Caudle to share practical strategies for integrating MCED into clinical workflows, addressing misconceptions, and streamlining follow-up protocols is Dr. Patrick McGill, board-certified family physician and Executive Vice President, Chief Transformation Officer at Community Health Network in Indianapolis.
Comments
Download from Google Play
Download from App Store
United States